PREGNANCY COURSE AND COMPLICATIONS IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS

被引:33
作者
RUBBERT, A
PIRNER, K
WILDT, L
KALDEN, JR
MANGER, B
机构
[1] UNIV ERLANGEN NURNBERG,DEPT OBSTET & GYNECOL,W-8520 ERLANGEN,GERMANY
[2] UNIV ERLANGEN NURNBERG,INST CLIN IMMUNOL & RHEUMATOL,W-8520 ERLANGEN,GERMANY
来源
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY | 1992年 / 28卷 / 3-4期
关键词
SLE; PREGNANCY; ANTIPHOSPHOLIPID; ANTIBODIES; COMPLEMENT-C3;
D O I
10.1111/j.1600-0897.1992.tb00792.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among 165 patients with systemic lupus erythematosus (SLE), we observed 21 pregnancies in 19 patients since 1987. The mean duration of disease at the time of pregnancy was 4.5 +/- 3 years. All but three patients required immunosuppressive treatment before and during pregnancy. The effect of pregnancy on the course of SLE was studied. Severe disease exacerbations were rare and largely confined to patients with renal involvement. Most patients showed elevated titers of dsDNA antibodies during pregnancy but clinical activity of disease was usually mild. Complement C3 decrease appeared to be the most sensitive marker for pregnancy-related complications. The detection of antibodies to phospholipids was frequent during pregnancy in contrast to a low prevalence before and after pregnancy. Their presence could be associated with intrauterine growth retardation. Preterm delivery before the 37th week of pregnancy had to be performed in the majority of patients. None of the patients experienced abortion although three patients had to be delivered in the 29th week of pregnancy because of increasing symptoms of preeclampsia. Two of these children died and the third child suffered from intracranial hemorrhage in the early postpartum period. Our data demonstrate that successful pregnancy outcome was related to a gestational age of more than 32 weeks, making careful monitoring and appropriate therapeutic management necessary.
引用
收藏
页码:205 / 207
页数:3
相关论文
共 12 条
[1]  
BAGULEY E, 1988, CLIN EXP RHEUMATOL, V6, P183
[2]   OBSTETRIC COMPLICATIONS ASSOCIATED WITH THE LUPUS ANTICOAGULANT [J].
BRANCH, DW ;
SCOTT, JR ;
KOCHENOUR, NK ;
HERSHGOLD, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (21) :1322-1326
[3]  
BRESNIHAN B, 1977, LANCET, V2, P1205
[4]   ACQUIRED CONGENITAL HEART-BLOCK - PATTERN OF MATERNAL ANTIBODY-RESPONSE TO BIOCHEMICALLY DEFINED ANTIGENS OF THE SSA/RO-SSB/LA SYSTEM IN NEONATAL LUPUS [J].
BUYON, JP ;
BENCHETRIT, E ;
KARP, S ;
ROUBEY, RAS ;
POMPEO, L ;
REEVES, WH ;
TAN, EM ;
WINCHESTER, R .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (02) :627-634
[5]   SERUM COMPLEMENT VALUES (C-3 AND C-4) TO DIFFERENTIATE BETWEEN SYSTEMIC LUPUS ACTIVITY AND PREECLAMPSIA [J].
BUYON, JP ;
CRONSTEIN, BN ;
MORRIS, M ;
TANNER, M ;
WEISSMANN, G .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (02) :194-200
[6]  
FRAGA A, 1974, J RHEUMATOL, V1, P293
[7]  
GIMOVSKY ML, 1982, OBSTET GYNECOL, V63, P686
[8]   IMMUNOLOGICAL STUDIES OF PLACENTA IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
GRENNAN, DM ;
MCCORMICK, JN ;
WOJTACHA, D ;
CARTY, M ;
BEHAN, W .
ANNALS OF THE RHEUMATIC DISEASES, 1978, 37 (02) :129-134
[9]  
KRAPF F, 1988, Z RHEUMATOL, V47, P292
[10]   LUPUS PREGNANCY - CASE-CONTROL PROSPECTIVE-STUDY DEMONSTRATING ABSENCE OF LUPUS EXACERBATION DURING OR AFTER PREGNANCY [J].
LOCKSHIN, MD ;
REINITZ, E ;
DRUZIN, ML ;
MURRMAN, M ;
ESTES, D .
AMERICAN JOURNAL OF MEDICINE, 1984, 77 (05) :893-898